Nuvalent (NUVL) Stock
Biotech company developing targeted cancer treatments. Here's the price, business snapshot, and what's worth knowing about Nuvalent in June 2026.
Nuvalent, Inc. (NUVL) is a clinical‑stage biotechnology company focused on precision oncology, developing targeted small‑molecule therapies against specific genetic drivers of cancer. With a market capitalisation of about $7.01 billion, the company’s value is largely driven by clinical trial progress, safety and efficacy readouts, regulatory milestones and potential collaborations or licensing deals rather than product revenue. Investors should expect higher volatility common to clinical‑stage biotechs: favourable trial results or partnerships can lift sentiment, while setbacks, delays or disappointing data can lead to sharp declines. Like many peers, Nuvalent may require additional funding as programmes advance, which can dilute existing shareholders. This summary is educational only and not personalised investment advice; prospective investors should assess their risk tolerance, consult multiple information sources (regulatory filings, clinical data and company statements) and consider professional financial guidance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Nuvalent's stock, believing it can rise above its current price.
Financial Health
Nuvalent Inc is showing strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring NUVL
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: 11 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision oncology focus
Develops targeted small‑molecule programmes against specific genetic drivers; scientific progress can attract partners, though trials carry inherent risk.
Catalysts to watch
Upcoming clinical readouts, regulatory milestones and collaboration announcements can move the stock significantly, but outcomes are uncertain.
Funding and partnerships
Partnerships may de‑risk programmes and add resources, while additional financing could dilute shareholders — both materially affect prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
